Eli Lilly’s stock rose nearly 5% in morning trading on Monday, reaching $1,286.10 and touching a fresh 52-week high of $1,289.97. The advance follows a 48% year-over-year revenue increase to $23 billion in the second quarter of 2026 and an upward revision to full-year revenue guidance to a range of $85 billion to $87 billion.
Prescription volumes for Foundayo, Eli Lilly’s oral GLP-1 obesity treatment, climbed 14% week-over-week to approximately 38,900, outpacing a roughly 5% decline in prescriptions for Novo Nordisk’s competing oral product, Wegovy. The data underscored Eli Lilly’s accelerating momentum in the oral obesity drug market.
The company also announced the acquisition of global rights to AlzeCure Pharma’s preclinical Alzheimer’s drug candidate, ACD680, with potential milestone payments exceeding $1 billion. Additionally, Eli Lilly entered a new global collaboration with OmniAb for an ion channel program, expanding its pipeline beyond metabolic disorders.
Barclays maintained its Buy rating on Eli Lilly stock on August 17, 2026, citing the company’s strong performance and growth outlook. The S&P 500 and Dow Jones Industrial Average edged higher by 0.1% and 0.2%, respectively, while the Nasdaq slipped 0.3% in broader market trading.
